Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T Cells In Situ and Lymph Node Metastasis
Table 2
The relationship between IDO expression and clinical pathological indexes.
IDO+SI (%)
value
Age (years)
<60
18
12.30 ± 8.35
0.465
≥60
8
15.11 ± 10.75
Menstrual status
Postmenopausal
14
15.02 ± 10.93
0.257
Nonpostmenopausal
12
10.83 ± 5.42
Tumor diameter (cm)
≤2
7
11.89 ± 6.55
0.211
2~5
15
13.43 ± 6.88
>5
4
14.38 ± 7.69
Clinical stage
I
2
8.95 ± 3.79
0.034
II
20
11.72 ± 6.48
III
4
22.47 ± 10.79*
Pathological type
Invasive Ductal Ca.
21
13.62 ± 9.39
0.223
Others
5
11.23 ± 6.25
histological grade
I
8
10.73 ± 6.45
0.324
II
10
12.29 ± 7.28
III
8
13.71 ± 5.96
TDLNs metastasis
pN0
6
10.29 ± 5.23
0.046
pN1
14
11.42 ± 8.49
pN2
4
15.98 ± 7.14
pN3
2
28.35 ± 14.78*
ER status
(−)
12
15.76 ± 10.58
0.394
(+)
14
12.70 ± 8.83
PR status
(−)
13
13.18 ± 8.02
0.624
(+)
13
15.29 ± 9.31
Her-2 status
(−)
18
11.69 ± 8.46
0.457
(+)
8
14.34 ± 10.23
*Statistically significant difference between the samples of advanced stage (stage III) and earlier stage (stage II and stage I), as well as the significant difference between the samples with more extensive LN metastasis (pN3) and less or no LN metastasis (pN0-2).
